MX346450B - Composiciones y métodos para el tratamiento de la enfermedad celíaca. - Google Patents

Composiciones y métodos para el tratamiento de la enfermedad celíaca.

Info

Publication number
MX346450B
MX346450B MX2011005632A MX2011005632A MX346450B MX 346450 B MX346450 B MX 346450B MX 2011005632 A MX2011005632 A MX 2011005632A MX 2011005632 A MX2011005632 A MX 2011005632A MX 346450 B MX346450 B MX 346450B
Authority
MX
Mexico
Prior art keywords
celiac disease
compositions
treatment
methods
treating
Prior art date
Application number
MX2011005632A
Other languages
English (en)
Other versions
MX2011005632A (es
Inventor
Robert Paul Anderson
Jessica Anne Stewart
James Anthony Dromey
Jason Allan Tyedin
Original Assignee
Immusant Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusant Inc * filed Critical Immusant Inc *
Publication of MX2011005632A publication Critical patent/MX2011005632A/es
Publication of MX346450B publication Critical patent/MX346450B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)

Abstract

La presente invención se refiere a agentes y vacunas para tratar y diagnosticar una enfermedad celiaca; en particular, la presente invención provee una combinación de tres péptidos que son útiles para tratar y diagnosticar una enfermedad celiaca en una gran proporción de pacientes.
MX2011005632A 2008-11-30 2009-11-30 Composiciones y métodos para el tratamiento de la enfermedad celíaca. MX346450B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11864308P 2008-11-30 2008-11-30
PCT/AU2009/001556 WO2010060155A1 (en) 2008-11-30 2009-11-30 Compositions and methods for treatment of celiac disease

Publications (2)

Publication Number Publication Date
MX2011005632A MX2011005632A (es) 2011-11-29
MX346450B true MX346450B (es) 2017-03-17

Family

ID=42225141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011005632A MX346450B (es) 2008-11-30 2009-11-30 Composiciones y métodos para el tratamiento de la enfermedad celíaca.

Country Status (16)

Country Link
US (5) US8835603B2 (es)
EP (3) EP2977053B1 (es)
JP (2) JP5851243B2 (es)
CN (2) CN102438643B (es)
AU (1) AU2009321481B2 (es)
BR (1) BRPI0922122A2 (es)
CA (2) CA2744787C (es)
DK (2) DK2977053T3 (es)
ES (2) ES2549481T3 (es)
HK (3) HK1162918A1 (es)
HR (1) HRP20150873T1 (es)
HU (1) HUE027237T2 (es)
MX (1) MX346450B (es)
NZ (1) NZ593474A (es)
PT (1) PT2367561E (es)
WO (1) WO2010060155A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
NZ550600A (en) 2004-04-28 2010-03-26 Btg Int Ltd Epitopes related to coeliac disease
JP5851243B2 (ja) 2008-11-30 2016-02-03 イミューサンティー インコーポレーテッドＩｍｍｕｓａｎＴ，Ｉｎｃ． セリアック病の処置のための組成物および方法
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN103282380B (zh) 2010-08-10 2018-02-16 洛桑聚合联合学院 红细胞结合性治疗剂
RU2635516C2 (ru) * 2011-01-20 2017-11-13 САЙРЕКС ЛАБОРАТОРИЗ, ЭлЭлСи Способы и устройство для обнаружения глютеновой чувствительности и ее дифференцирования с целиакией
ITRM20110487A1 (it) * 2011-09-19 2013-03-20 Consiglio Per La Ricerca E La Speri Mentazione In Peptidi aventi effetto protettivo nei confronti della attività infiammatoria del peptide 31-43 della a-gliadina nella malattia celiaca.
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
CA3191015A1 (en) 2012-02-07 2013-08-15 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
PT2863942T (pt) 2012-06-21 2019-07-17 Univ Northwestern Partículas conjugadas a peptídeo
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
CA2932532C (en) 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
KR20210057832A (ko) 2013-03-13 2021-05-21 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 염증 치료용 면역-변형된 입자
AU2014240046A1 (en) * 2013-03-14 2015-10-08 Robert P. Anderson Placebo-controlled gluten challenge method
EP2994480A4 (en) * 2013-05-08 2017-05-17 JM Biologicals Compositions and methods for the production of gluten free food products
HUE047329T2 (hu) 2013-08-13 2020-04-28 Univ Northwestern Peptiddel konjugált részecskék
EP3043812A1 (en) 2013-09-10 2016-07-20 Immusant Inc. Dosage of a gluten peptide composition
WO2015041680A1 (en) * 2013-09-20 2015-03-26 Immusant, Inc. Compositions and methods related to oat sensitivity
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10821157B2 (en) 2014-02-21 2020-11-03 Anokion Sa Glycotargeting therapeutics
US20170232083A1 (en) * 2014-04-24 2017-08-17 Immusant, Inc. Methods of diagnosis and treatment of celiac disease in children
JP6887945B2 (ja) * 2014-09-10 2021-06-16 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー セリアック病に関するペプチドマイクロアレイおよび新規バイオマーカー
WO2016054038A1 (en) * 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
AU2015349728A1 (en) * 2014-11-21 2017-07-13 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
KR101736744B1 (ko) 2014-12-03 2017-05-17 주식회사 한국유전자정보연구원 셀리악병 진단용 프라이머 세트와 이를 이용한 셀리악병 진단방법
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017058074A1 (en) * 2015-08-30 2017-04-06 Diamyd Medical Ab Combination therapy using gliadin and gamma aminobutyric acid
EP3393514A4 (en) 2015-12-23 2019-08-14 Cour Pharmaceuticals Development Company Inc. PARTICLES CONJUGATED BY COVALENCE OF THE POLYMER-ANTIGEN TYPE
EP3416624B8 (en) 2016-02-18 2023-08-23 Cour Pharmaceuticals Development Company Inc. Process for the preparation of tolerizing immune-modulating particles
WO2017212476A1 (en) * 2016-06-05 2017-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Novel molecules for the treatment of inflammation
EP3474881A1 (en) 2016-06-28 2019-05-01 Immusant, Inc. Escalating dosage schedules for treating celiac disease
US11166993B2 (en) * 2017-01-12 2021-11-09 Probi Ab Methods for celiac disease using lactobacillus strains
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
AU2018327224A1 (en) 2017-09-07 2020-04-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
WO2019089572A1 (en) * 2017-10-30 2019-05-09 Immusant, Inc. Dosing regimens for celiac disease
JP6568193B2 (ja) 2017-12-19 2019-08-28 ホーユー株式会社 エピトープ
CA3090777A1 (en) * 2018-02-08 2019-08-15 Cour Pharmaceuticals Development Company Inc. Treatment of celiac disease with tolerizing particles
CN113227124A (zh) * 2018-10-31 2021-08-06 味之素株式会社 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
WO2020181272A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
JP7374687B2 (ja) * 2019-09-26 2023-11-07 三和酒類株式会社 ペンタペプチド化合物
EP4061403A4 (en) * 2019-11-19 2023-12-27 Spark Therapeutics, Inc. SECRETABLE PROTEIN-INDUCED IMMUNE TOLERANCE AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS
BR112023021222A2 (pt) 2021-04-16 2024-01-16 Cour Pharmaceuticals Dev Company Inc Método de rastreamento de manutenção de tolerância imunológica
WO2024020127A1 (en) 2022-07-21 2024-01-25 Antiva Biosciences, Inc. Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740371A (en) 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
JP2642112B2 (ja) 1986-03-06 1997-08-20 コモンウエルス サイエンテイフイック アンド インダストリアル リサーチ オーガナイゼイシヨン 細胞性免疫応答検出用インビトロ分析
FR2615622B1 (fr) 1987-05-19 1994-05-06 Ire Medgenix Sa Dosage plasmatique de monokines
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5998366A (en) 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
IL105153A (en) 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JPH10511541A (ja) 1994-08-26 1998-11-10 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｔ細胞応答を調節するための方法および組成物
US6759234B1 (en) 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
EP0783322A1 (en) 1994-09-02 1997-07-16 Immunologic Pharmaceutical Corporation Peptide compositions capable of down regulating an antigen specific immune response
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
EP0905518A1 (en) 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
EP1241476A1 (en) 2001-03-12 2002-09-18 Mabtech AB Diagnosis of metal allergy through cytokine release by T-cells in vitro
WO2002080963A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
WO2002083722A2 (en) 2001-04-12 2002-10-24 Academisch Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
FI20010868A0 (fi) 2001-04-25 2001-04-25 Markku Maeki Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi
WO2003047618A2 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
EP1332760A1 (en) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
ES2361993T5 (es) 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
CA2487247A1 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
AU2002952834A0 (en) 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
AU2003277989B2 (en) 2002-11-08 2010-04-22 QIAGEN Australia Holding Pty. Ltd. Diagnostic assay for measuring a cell mediated immune response
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
ES2383595T3 (es) 2002-11-20 2012-06-22 The Board Of Trustees Of The Leland Stanford Junior University Procedimiento de diagnóstico de la celiaquía
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
NZ550600A (en) * 2004-04-28 2010-03-26 Btg Int Ltd Epitopes related to coeliac disease
GB0409775D0 (en) 2004-04-30 2004-06-09 Mabtech Ab Assay
CA2585462A1 (en) 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
WO2007022477A2 (en) 2005-08-17 2007-02-22 Multicell Immunotherapeutics, Inc. Methods and compositions to generate and control the effector profile of t cells
US20090304754A1 (en) 2005-10-12 2009-12-10 Srebrenka Robic Pegylated glutenase polypeptides
AU2007238595A1 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
EP3351268B1 (en) * 2007-01-25 2020-08-05 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
ITFE20070003A1 (it) 2007-02-01 2007-05-03 Girolamo Calo' Utilizzo di peptidi ricchi in prolina e glutamina capaci di legarsi alle molecole hla-dq2 e dq8 come "carriers specifici" di agenti capaci di danneggiare o uccidere le cellule che esprimono dette molecole hla nel contesto dell a mucosa enterica di pa
AU2008229636B2 (en) 2007-03-16 2014-08-14 QIAGEN Australia Holding Pty. Ltd. A cell-mediated immune response assay and kits therefor
WO2009131909A2 (en) 2008-04-21 2009-10-29 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
CA2722996A1 (en) 2008-05-16 2009-11-19 Michael Thomas Bethune Non-inflammatory gluten peptide analogues as biomarkers for celiac sprue
JP2011529171A (ja) 2008-07-25 2011-12-01 セレスティス リミテッド 診断方法
JP5851243B2 (ja) 2008-11-30 2016-02-03 イミューサンティー インコーポレーテッドＩｍｍｕｓａｎＴ，Ｉｎｃ． セリアック病の処置のための組成物および方法
WO2011000773A1 (en) 2009-07-02 2011-01-06 Dsm Ip Assets B.V. Testing efficacy for celiac disease
CN109100501B (zh) 2009-12-23 2022-05-13 塞尔雷斯蒂斯有限公司 测量细胞介导免疫反应的试验
EP2577307B1 (en) 2010-05-28 2019-05-22 Cellestis Limited A diagnostic assay
US20110311536A1 (en) 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
RU2018107763A (ru) 2011-06-29 2019-02-25 Селлестис Лимитед Способ анализа клеточно-опосредованного иммунного ответа с повышенной чувствительностью
EP2736525A1 (en) 2011-07-25 2014-06-04 Alvine Pharmaceuticals, Inc. Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
WO2013036300A1 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Compositions and methods related to induced tolerogenic dedritic cells externally loaded with mhc class i-restricted epitopes
ES2402286B1 (es) 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
EP3171171B1 (en) 2011-12-05 2018-07-18 Bio-rad Laboratories, Inc. Recombinant deamidated gliadin antigen
AU2014240046A1 (en) 2013-03-14 2015-10-08 Robert P. Anderson Placebo-controlled gluten challenge method
EP3043812A1 (en) 2013-09-10 2016-07-20 Immusant Inc. Dosage of a gluten peptide composition
WO2015041680A1 (en) 2013-09-20 2015-03-26 Immusant, Inc. Compositions and methods related to oat sensitivity
US20170232083A1 (en) 2014-04-24 2017-08-17 Immusant, Inc. Methods of diagnosis and treatment of celiac disease in children

Also Published As

Publication number Publication date
EP2977053B1 (en) 2017-07-05
CA3042826A1 (en) 2010-06-03
WO2010060155A1 (en) 2010-06-03
DK2977053T3 (en) 2017-10-09
HK1219898A1 (zh) 2017-04-21
HK1162918A1 (en) 2012-09-07
JP2016128402A (ja) 2016-07-14
JP6027215B2 (ja) 2016-11-16
AU2009321481A1 (en) 2011-07-07
US20150050303A1 (en) 2015-02-19
US20210115096A1 (en) 2021-04-22
EP2367561A1 (en) 2011-09-28
US9464120B2 (en) 2016-10-11
CA2744787A1 (en) 2010-06-03
US20170158743A1 (en) 2017-06-08
CN102438643A (zh) 2012-05-02
BRPI0922122A2 (pt) 2017-08-01
CN105079781B (zh) 2018-07-20
ES2549481T3 (es) 2015-10-28
EP2367561A4 (en) 2012-06-06
AU2009321481B2 (en) 2014-08-21
EP2367561B1 (en) 2015-05-20
HK1249446A1 (zh) 2018-11-02
CN102438643B (zh) 2015-07-01
US8835603B2 (en) 2014-09-16
JP5851243B2 (ja) 2016-02-03
PT2367561E (pt) 2015-10-23
US20190048047A1 (en) 2019-02-14
NZ593474A (en) 2013-04-26
CN105079781A (zh) 2015-11-25
ES2642096T3 (es) 2017-11-15
EP2977053A1 (en) 2016-01-27
JP2012510431A (ja) 2012-05-10
US20110293644A1 (en) 2011-12-01
HRP20150873T1 (hr) 2015-11-06
HUE027237T2 (en) 2016-10-28
DK2367561T3 (en) 2015-08-24
CA2744787C (en) 2019-06-11
EP3269379A1 (en) 2018-01-17
MX2011005632A (es) 2011-11-29

Similar Documents

Publication Publication Date Title
MX346450B (es) Composiciones y métodos para el tratamiento de la enfermedad celíaca.
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
MX355543B (es) Macrociclos peptidomiméticos.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX350046B (es) Tratamientos para trastornos gastrointestinales.
MX2012011543A (es) Tratamiento de sarcoidosis empleando celulas madre placentarias.
PH12014501844A1 (en) Peptidomimetic macrocycles
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
WO2010083347A3 (en) Peptidomimetic macrocycles
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
IN2012DN06309A (es)
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
GB2497475A (en) Kits, components and methods for tissue reconstruction
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
EA201200428A1 (ru) Композиция и способ для лечения ожирения
WO2011097522A3 (en) Combination methods for treatment of disease
MY155340A (en) Use of cathepsin c
MX2012012479A (es) Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.

Legal Events

Date Code Title Description
FG Grant or registration